Jafron Biomedical (300529) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

300529 Jafron Biomedical

Watchlist

29.65
+0.87+3.02%

Market Closed Jan 17 15:00 CST

23.68BMarket Cap29.44P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Are Jafron Biomedical Co.,Ltd.'s (SZSE:300529) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Simply Wall StJan 17 17:58 ET
Market Still Lacking Some Conviction On Jafron Biomedical Co.,Ltd. (SZSE:300529)
Simply Wall StDec 30, 2024 17:37 ET
Jafron Biomedical Unit Obtains EU Certification for Plasma Separator Product
MT NewswiresDec 13, 2024 03:27 ET
CEO Fan Dong, Jafron Biomedical Co.,Ltd.'s (SZSE:300529) Largest Shareholder Sees Value of Holdings Go Down 4.5% After Recent Drop
Simply Wall StNov 22, 2024 19:35 ET
Jafron BiomedicalLtd's (SZSE:300529) 84% YoY Earnings Expansion Surpassed the Shareholder Returns Over the Past Year
Simply Wall StNov 7, 2024 18:48 ET
Jafron Biomedical Co.,Ltd. Just Missed Revenue By 8.1%: Here's What Analysts Think Will Happen Next
Simply Wall StOct 21, 2024 18:19 ET

Comments

Moomoo AI

Mar 14, 2024 19:59

The EPS decline has disappointed the market, leaving investors hesitant to buy. Shareholders face a total loss of 3% per year over five years due to the company's poor performance.

Jafron BiomedicalLtd's (SZSE:300529) Earnings Trajectory Could Turn Positive as the Stock Increases 7.1% This Past Week

Moomoo AI

Feb 7, 2024 16:20

The trend of decreasing ROCE and revenue despite increased capital deployment is concerning, suggesting the company may be losing its competitive advantage or market share. The stock has remained flat over the last five years, indicating investors are not impressed with these trends.

Jafron BiomedicalLtd (SZSE:300529) Is Reinvesting At Lower Rates Of Return

Moomoo AI

Feb 1, 2024 01:17

Suntront Technology's low P/E ratio is due to its declining medium-term earnings and the market's growth expectations. Investors think the potential for earnings improvement doesn't justify a higher P/E ratio. If recent earnings trends persist, the share price may not fluctuate significantly soon.

Earnings Working Against Suntront Technology Co., Ltd.'s (SZSE:300259) Share Price

Moomoo AI

Jan 20, 2024 18:40

Despite a recent earnings dip, Jafron Biomedical's high P/E ratio is justified by its promising earnings outlook. Investors anticipate robust future growth, outweighing any potential earnings deterioration.

What You Can Learn From Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E

Moomoo AI

Oct 22, 2023 23:37

Concerns mount as Jafron BiomedicalLtd's returns shrink amidst rising capital investments. The stagnant sales and ineffective growth reinvestment may result in market share loss. Time to seek other investment opportunities?